Dignitana AB

Dignitana AB is a Swedish medical technology company specializing in scalp cooling systems for cancer patients undergoing chemotherapy. The company manufactures and markets The DigniCap Scalp Cooling System, a patented medical device designed to minimize hair loss during chemotherapy treatment, thereby improving patient well-being and quality of life. The DigniCap system received FDA clearance in 2015 and expanded clearance in 2017 for use in patients receiving chemotherapy to treat solid tumors including breast cancer, prostate, ovarian, uterine, and lung cancers. Clinical pivotal trial data demonstrated that 67% of patients achieved successful outcomes and retained their hair. The system provides continuous cooling with documented efficacy, safety, and acceptable patient comfort profiles. As of June 1, 2025, Dignitana became a wholly owned subsidiary of the Paxman Group. The company operates through three subsidiaries: Dignitana AB (headquarters in Lund, Sweden), Dignitana US Inc. (Dallas, Texas), and Dignitana SRL (Milan, Italy). The organization serves oncology centers and cancer treatment facilities globally, supporting patients and healthcare providers in managing chemotherapy-related side effects.